New NDF Report. Looks Good!!, page-10

NDF Research

ResApp Health (ASX: RAP) Update note – Friday 30 June 2017

First major clinical study of ResAppDx reports important data

This note updates our Initiation Report of 25 July 2016 headlined ‘The Next Big Thing in Respiratory Diagnostics’. ResApp Health has just reported important data from the first major clinical study of the ResAppDx, a smartphone-based diagnostic for respiratory disease which we have previously called the ResApp System. This Australian study in pediatric patients was not a study for registration purposes but has shown that the ResAppDx works very well as a diagnostic across a broad range of childhood respiratory diseases (including upper respiratory tract infection, croup, bronchiolitis, pneumonia and asthma), each of which provides a clinically-valuable diagnosis. ResApp’s US study in pediatric patients, which is being conducted to gain FDA approval, has now completed recruitment and ResApp’s investigators will now evaluate the data using the algorithms perfected during the Australian Pediatric Study. Should the US Pediatric Study be successful, we expect a filing shortly for De Novo approval in the second half of 2017, with approval expected in late 2017 or early 2018.
Rating Buy
Risk Medium
Current price $0.30
Target price $0.85